Cargando…
Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients
In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against S. pneumoniae is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate tha...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706129/ https://www.ncbi.nlm.nih.gov/pubmed/34960184 http://dx.doi.org/10.3390/vaccines9121438 |
_version_ | 1784622117563662336 |
---|---|
author | Gäckler, Anja Mülling, Nils Völk, Kim Wilde, Benjamin Eisenberger, Ute Rohn, Hana Horn, Peter A. Witzke, Oliver Lindemann, Monika |
author_facet | Gäckler, Anja Mülling, Nils Völk, Kim Wilde, Benjamin Eisenberger, Ute Rohn, Hana Horn, Peter A. Witzke, Oliver Lindemann, Monika |
author_sort | Gäckler, Anja |
collection | PubMed |
description | In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against S. pneumoniae is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate that transplant recipients can produce specific antibodies after pneumococcal vaccination. However, it remains unclear if vaccination also induces specific cellular immunity. In the current study on 38 kidney transplant recipients, we established an interferon-γ ELISpot assay that can detect serotype-specific cellular responses against S. pneumoniae. The results indicate that sequential vaccination with the conjugated vaccine Prevenar 13 and the polysaccharide vaccine Pneumovax 23 led to an increase of serotype-specific cellular immunity. We observed the strongest responses against the serotypes 9N and 14, which are both components of Pneumovax 23. Cellular responses against S. pneumoniae correlated positively with specific IgG antibodies (r = 0.32, p = 0.12). In conclusion, this is the first report indicating that kidney transplant recipients can mount specific cellular responses after pneumococcal vaccination. The ELISpot we established will allow for further investigations. These could help to define, for example, factors influencing specific cellular immunity in immunocompromised cohorts or the duration of cellular immunity after vaccination. |
format | Online Article Text |
id | pubmed-8706129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87061292021-12-25 Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients Gäckler, Anja Mülling, Nils Völk, Kim Wilde, Benjamin Eisenberger, Ute Rohn, Hana Horn, Peter A. Witzke, Oliver Lindemann, Monika Vaccines (Basel) Article In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against S. pneumoniae is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate that transplant recipients can produce specific antibodies after pneumococcal vaccination. However, it remains unclear if vaccination also induces specific cellular immunity. In the current study on 38 kidney transplant recipients, we established an interferon-γ ELISpot assay that can detect serotype-specific cellular responses against S. pneumoniae. The results indicate that sequential vaccination with the conjugated vaccine Prevenar 13 and the polysaccharide vaccine Pneumovax 23 led to an increase of serotype-specific cellular immunity. We observed the strongest responses against the serotypes 9N and 14, which are both components of Pneumovax 23. Cellular responses against S. pneumoniae correlated positively with specific IgG antibodies (r = 0.32, p = 0.12). In conclusion, this is the first report indicating that kidney transplant recipients can mount specific cellular responses after pneumococcal vaccination. The ELISpot we established will allow for further investigations. These could help to define, for example, factors influencing specific cellular immunity in immunocompromised cohorts or the duration of cellular immunity after vaccination. MDPI 2021-12-06 /pmc/articles/PMC8706129/ /pubmed/34960184 http://dx.doi.org/10.3390/vaccines9121438 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gäckler, Anja Mülling, Nils Völk, Kim Wilde, Benjamin Eisenberger, Ute Rohn, Hana Horn, Peter A. Witzke, Oliver Lindemann, Monika Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title | Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title_full | Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title_fullStr | Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title_full_unstemmed | Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title_short | Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients |
title_sort | establishment of an elispot assay to detect cellular immunity against s. pneumoniae in vaccinated kidney transplant recipients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706129/ https://www.ncbi.nlm.nih.gov/pubmed/34960184 http://dx.doi.org/10.3390/vaccines9121438 |
work_keys_str_mv | AT gackleranja establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT mullingnils establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT volkkim establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT wildebenjamin establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT eisenbergerute establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT rohnhana establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT hornpetera establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT witzkeoliver establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients AT lindemannmonika establishmentofanelispotassaytodetectcellularimmunityagainstspneumoniaeinvaccinatedkidneytransplantrecipients |